NeuroVive Admitted to Trading on NASDAQ OMX Stockholm

            NeuroVive Admitted to Trading on NASDAQ OMX Stockholm

  PR Newswire

  LUND, Sweden, March 25, 2013

LUND, Sweden, March 25, 2013 /PRNewswire/ --

NeuroVive, a leading mitochondrial medicine company, announces that its shares
have been approved for listing on NASDAQ OMX Stockholm by the exchange's
Listing Committee. The first day of trading on NASDAQ OMX Stockholm will be
April 10th and the last day of trading on the Swedish trading platform
AktieTorget will be April 9th.

The stock will be traded under the same ticker symbol, NVP. No new shares will
be issued in conjunction with the listing on NASDAQ OMX Stockholm.

Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said: "Our move to NASDAQ
OMX Stockholm is an important step forward in the growth and development of
our company. Through this listing NeuroVive will gain access to a broader and
deeper pool of investors that will be vital as we look to finance our strategy
which is designed to maximize shareholder value from our leading position in
mitochondrial medicine."

About NeuroVive Pharmaceutical AB (publ)

NeuroVive Pharmaceutical AB ( http://www.neurovive.com ) a leading
mitochondrial medicine company is developing a portfolio of products to treat
acute cardiovascular and neurological conditions through mitochondrial
protection.

NeuroVive's products are based on the cyclophilin inhibitor, cyclosporine, and
work by preventing the death of mitochondria in distressed cells and the
subsequent cascade of intracellular biochemical events that lead to secondary
tissue damage following an acute cardiac or traumatic brain injury.

NeuroVive's lead product is CicloMulsion®, the first cyclophilin inhibitor for
the treatment of reperfusion injuries following cardiac stenting.
CicloMulsion® is currently in a 1000 patient Phase III clinical trial
evaluating its ability to reduce reperfusion injuries in patients with
myocardial infarction.

NeuroVive is also developing NeuroSTAT®, a cyclophilin inhibitor, which is
entering a Phase IIa clinical trial in patients with severe traumatic brain
injury. Both indications have huge medical need and for which there are
currently no approved pharmaceutical treatment options. Both CicloMulsion® and
NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac
and brain injury indications.

NeuroVive's pipeline includes novel cyclophilin inhibitors, and drug
candidates that act on mitochondria to address energy regulation disorders.

NeuroVive´s shares are listed on the Swedish trading platform AktieTorget (
http://www.aktietorget.se ). The AktieTorget market is focused on emerging,
entrepreneurial businesses through an electronic trading system supplied by
the OMX Nordic stock exchange in Stockholm, Sweden.

Media and investor relations contacts NeuroVive Pharmaceutical: Mikael
Bronnegard Email: info@neurovive.com Phone No: +46(0)70-299-62-64 Citigate
Dewe Rogerson: Nina Enegren / David Dible Email: nina.enegren@citigatedr.co.uk
Phone No: +44(0)207-282-1050
 
Press spacebar to pause and continue. Press esc to stop.